Navigation Links
First Catalog Cancer Biochip for Sequence Capture Now Available from febit
Date:7/13/2009

LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 /PRNewswire/ -- febit holding gmbh announced today the launch of the first human cancer biochip for HybSelect, febit's highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute.

"Molecular signatures defined by large-scale gene expression profiling are at the forefront in developing new biomarkers and identifying new therapeutic targets," said Professor Eckart Meese, director of the Department of Human Molecular Genetics at Saarland University. "It is of utmost importance for our research on malignant brain cancer to obtain deep sequencing results of the 100 most relevant genes with high sequence coverage using the HybSelect technique. It is equally important to obtain these results within a short period of time and at low costs."

The availability of the automated HybSelect technology supports large-cohort NGS studies that aim to elucidate complex diseases such as cancer, drive forward personalized medicine and investigate new therapeutic delivery models. febit will stay at the forefront of cancer research and include key research study results in the next generation of febit's cancer biochips. A 2Mb exon cancer biochip will be available this summer and a 30Mb biochip is planned already for release in 2010.

Multiplex NGS studies based on sequence capture can be supplemented by other molecular fingerprinting methods, including mRNA and miRNA expression profiling. Both of these high-throughput methods can be performed using the same febit technology as HybSelect, thereby reducing capital expenditures and minimizing experimental variation. HybSelect and expression profiling can easily be performed in the researcher's lab operating a Geniom RT Analyzer from febit or by using febit's convenient Analytical Services.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

For its main applications -- HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing and protein-coding or non-coding transcriptome profiling -- the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.

For more information, please visit www.febit.com.

    Contact:

    febit group
    Eva Sterzel
    eva.sterzel@febit.com
    +49 (0)6221 6510-300

    Russo Partners
    Martina Schwarzkopf
    martina.schwarzkopf@russopartnersllc.com
    +1 212 845-4292


'/>"/>
SOURCE febit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
2. First step to converting solar energy using artificial leaf
3. Bio/Data Corporation Launches vW Select(TM) - The Worlds First and Only Complete Ristocetin CoFactor Assay
4. febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment
5. Scientists create first electronic quantum processor
6. Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training
7. First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S.
8. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
9. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
10. Virtify, Inc. Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies
11. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):